Orforglipron

Orforglipron (LY3502970; CAS 2212020-52-3; molecular formula C42H55F3N6O5; molecular weight 781.07) is a small-molecule non-peptide GLP-1 receptor agonist developed by Eli Lilly through licensing of a chemical series originated by Chugai Pharmaceutical and further optimized at Lilly. The compound is the first true small-molecule oral GLP-1 agonist to enter Phase 3 clinical trials; the only previously marketed oral GLP-1 agonist is the peptide-class oral semaglutide (Rybelsus), which requires the SNAC absorption-enhancer formulation and a strict fasted-state administration protocol owing to the intrinsically poor oral bioavailability of peptide GLP-1 agonists. The non-peptide structure of orforglipron eliminates the absorption challenge: oral bioavailability is approximately 30 to 60 percent without absorption enhancers and without strict fasting requirements; the compound is an allosteric agonist that binds at a site distinct from the GLP-1 peptide binding pocket, producing receptor activation through a non-peptide chemical scaffold. Phase 2 obesity results published in 2023 reported approximately 14.7 percent body weight reduction at 36 weeks at the highest dose, comparable to subcutaneous semaglutide and meaningfully greater than oral semaglutide at clinically used doses. Phase 2 type 2 diabetes results showed glycated hemoglobin reduction up to 2.1 percent at the highest dose. The compound is in active Phase 3 development in obesity (ATTAIN program) and type 2 diabetes (ACHIEVE program) with anticipated regulatory submissions in 2025 to 2026. Side effect profile parallels other GLP-1 agonists (nausea, vomiting, diarrhea) with somewhat more rapid onset of adverse events at initiation, attributed to the rapid absorption profile of the small molecule versus the slow titration enabled by long-acting injectable peptides. Orforglipron represents a category-shifting development in the GLP-1 class: oral, simple administration, and competitive efficacy.